Johnson & Johnson (NYSE:JNJ) reported two-year findings for IMAAVY in adolescents with generalized myasthenia gravis (gMG), along with results from a retrospective survey evaluating adults who switched to the therapy from other advanced treatments.
Aldeyra Therapeutics (NASDAQ:ALDX) announced plans to submit a Formal Dispute Resolution Request (FDRR) to the U.S. Food and Drug Administration (FDA) seeking review of the agency’s decision not to approve reproxalap, its investigational therapy for dry eye disease.
Unicycive Therapeutics (NASDAQ:UNCY) resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for oxylanthanum carbonate, an investigational treatment for hyperphosphatemia in patients receiving dialysis.
uniQure (NASDAQ:QURE) reported additional Phase I/II data for ifezuntirgene inilparvovec, its investigational gene therapy for Huntington’s disease, with follow-up results extending to 36 and 48 months.
Invivyd (NASDAQ:IVVD) reported Phase 3 LIBERTY trial results showing that its investigational COVID-19 antibody product VYD2311 demonstrated fewer reported adverse events compared with an mRNA COVID-19 vaccine.
IM Cannabis (NASDAQ:IMCC) completed the sale of IMC Holdings to Slil, following a transaction that included a previously paid C$3 million payment as part of the consideration.
Eli Lilly (NYSE:LLY) reported an indirect comparison suggesting that Zepbound 10 mg and 15 mg were associated with greater weight loss than Wegovy HD 7.2 mg in adults with obesity.
Kura Oncology (NASDAQ:KURA) and Caspian Therapeutics presented preclinical findings for KO-7246, an investigational diabetes treatment candidate, at the European Association for the Study of Diabetes (EASD) meeting in Milan.
Jaguar Health (NASDAQ:JAGX) announced that an abstract covering preliminary results from an adult short bowel syndrome study has been accepted for presentation at the American College of Gastroenterology (ACG) 2026 meeting.
HUTCHMED (NASDAQ:HCM) announced that AstraZeneca (NASDAQ:AZN) submitted a U.S. regulatory application for ORPATHYS in combination with TAGRISSO for patients with MET-driven EGFR-mutated non-small cell lung cancer.
Evotec (NASDAQ:EVO) announced that Chief Scientific Officer Cord Dohrmann will step down from his role on September 30, 2026, by mutual consent.
Novo Nordisk (NYSE:NVO) agreed to license Hengrui Pharma’s phase 1-ready oral candidate HRS-1596 in a transaction valued at up to $2.6 billion.
